EXEL
Exelixis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About EXEL
Exelixis, Inc.
A biotech company that develops novel small molecule therapies to treat cancer
1851 Harbor Bay Parkway, Alameda, California 94502
--
Exelixis, Inc., is a biotechnology company engaged in the development of small molecule therapies for cancer. The Company was incorporated in Delaware as Exelixis Pharmaceuticals, Inc., in November 1994 and changed to Exelixis, Inc., in February 2000. The company's resources, R & D, and production focus on COMETRIQ (cabozantinib capsules, the company's wholly-owned multi-target receptor tyrosine kinase inhibitor). The company aims to develop COMETRIQ into a major licensed oncology product, and believes that the approval of COMETRIQ's treatment of deteriorating, metastatic MTC provides an opportunity to achieve this goal and establish a commercial position.
Earnings Call
Q1/2025
Estimate EPS0.44
Actual EPS0.62
Estimate Revenue500.96M
Actual Revenue555.45M
Exelixis Q1 2025: Key Contradictions on NET Market Potential, Business Segmentation, and Competitive Positioning
May 20,2025 02:29
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.64
Actual EPS0.75
Estimate Revenue579.47M
Actual Revenue568.30M
Navigating Contradictions: Insights from the Latest Earnings Call on NET Revenue, Pricing Dynamics, and Zanzalintinib's Strategy
Jul 28,2025 11:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
EXEL has released its 2025 Q3 earnings. EPS was reported at 0.78, versus the expected 0.67, beating expectations. The chart below visualizes how EXEL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
EXEL has released its 2025 Q3 earnings report, with revenue of 597.75M, reflecting a YoY change of 10.79%, and net profit of 193.58M, showing a YoY change of 64.09%. The Sankey diagram below clearly presents EXEL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
